Chinese Biotech Firm LianBio Prices US$325 Million Nasdaq IPO Biotech company LianBio (Nasdaq: LIAN) started trading on the Nasdaq Global Market today. The Shanghai-based firm aims to raise approximately US$325 million in its debut on the US big board. The offering consisted of 20,312,500 American depositary shares at US$16.00 per ADS, which represents 1 ordinary company share. The ADSs will be trading on the Nasdaq exchange under the symbol “LIAN”. Goldman Sachs & Co., Jefferies, and BofA Securities, Inc. are acting as the joint bookrunners for the said offering. The underwriters were given a 30-day over-allotment option to purchase up...